Syncromune, Inc.

Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to developing SYNC-T, a potentially first-in-class, in situ personalized combination immunotherapy platform. The company focuses on developing transformative therapies for metastatic solid tumor cancers, aiming to synchronize the immune system to recognize and attack cancer throughout the body. Their goal is to provide potential curative benefits for patients with incurable metastatic solid tumors.